DRKS00017740进行中（未招募）不适用
Tofacitinib Registry of patients with ulcerative colitis in Germany - TOFAuc-Registry
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •Patients with moderate to severe Ulcerative Colitis aged 18-80 years at enrollment
- •- Written informed consent is given
- •- New tofacitinib/biologics therapy started
排除标准
- •- Malignant disease in history (except for non-melanoma skin cancer)
- •- Any contraindication according to the SmPC of the respective medication
研究者
相似试验
终止
不适用
Tofacitinib Registry of Patients With Ulcerative Colitis in GermanyColitis, UlcerativeBiologicsTofacitiniibChronic Inflammatory Small Bowel DiseaseBowel Diseases, InflammatoryBowel DiseaseCEDNCT04032756Ced Service GmbH50
进行中（未招募）
1 期
Research with the drug tofacitinib for patients with refractory celiac disease type IIRefractory celiac disease type IIEUCTR2018-001678-10-NLVU Medical Center5
招募中
2 期
Tofacitinib: salvage therapy for patients with RCDII - a pilot studygluten intolerancerefractory celiac disease type II1002532110017969NL-OMON52502Vrije Universiteit Medisch Centrum4
尚未招募
3 期
Tofacitinib in skin calcifications in childhood myositisCTRI/2024/02/062740Department of Pediatrics, AIIMS, New Delhi
招募中
3 期
Efficacy and safety of tofacitinib on clinical improvement in patients with COVID19COVID-19 pneumonia.Covid-19 diseaseU07.1IRCT20190804044429N7Mazandaran University of Medical Sciences240